BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 16529031)

  • 21. Prognostic applications of gene expression signatures in breast cancer.
    Normanno N; De Luca A; Carotenuto P; Lamura L; Oliva I; D'Alessio A
    Oncology; 2009; 77 Suppl 1():2-8. PubMed ID: 20130425
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Breast cancer molecular subtypes in patients with locally advanced disease: impact on prognosis, patterns of recurrence, and response to therapy.
    Huber KE; Carey LA; Wazer DE
    Semin Radiat Oncol; 2009 Oct; 19(4):204-10. PubMed ID: 19732684
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Breast cancer biomarkers and molecular medicine: part II.
    Ross JS; Linette GP; Stec J; Clark E; Ayers M; Leschly N; Symmans WF; Hortobagyi GN; Pusztai L
    Expert Rev Mol Diagn; 2004 Mar; 4(2):169-88. PubMed ID: 14995904
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integrated gene expression profile predicts prognosis of breast cancer patients.
    Li LF; Xu XJ; Zhao Y; Liu ZB; Shen ZZ; Jin WR; Shao ZM
    Breast Cancer Res Treat; 2009 Jan; 113(2):231-7. PubMed ID: 18278552
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene expression profiling in breast cancer: towards individualising patient management.
    Murphy N; Millar E; Lee CS
    Pathology; 2005 Aug; 37(4):271-7. PubMed ID: 16194824
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Technology insight: Emerging techniques to predict response to preoperative chemotherapy in breast cancer.
    Pusztai L; Gianni L
    Nat Clin Pract Oncol; 2004 Nov; 1(1):44-50. PubMed ID: 16264799
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of breast cancer in the genome era.
    Morrow PK; Hortobagyi GN
    Annu Rev Med; 2009; 60():153-65. PubMed ID: 19630569
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transcriptomic signatures in breast cancer.
    Fu J; Jeffrey SS
    Mol Biosyst; 2007 Jul; 3(7):466-72. PubMed ID: 17579771
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Genomic based approach to individualized cancer therapy].
    Isomura M; Miki Y
    Nihon Rinsho; 2010 Jun; 68(6):1117-20. PubMed ID: 20535965
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of mdr1 gene expression with other prognostic factors and clinical outcome in human breast cancer.
    Punyammalee B; Manoromana S; Purisa W; Chariyalertsak S; Rerkamnuaychok B
    J Med Assoc Thai; 1997 Sep; 80 Suppl 1():S162-73. PubMed ID: 9347665
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNA profiling as a tool to understand prognosis, therapy response and resistance in breast cancer.
    Iorio MV; Casalini P; Tagliabue E; Ménard S; Croce CM
    Eur J Cancer; 2008 Dec; 44(18):2753-9. PubMed ID: 19022662
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular prediction of the therapeutic response to neoadjuvant chemotherapy in breast cancer.
    Nagasaki K; Miki Y
    Breast Cancer; 2008; 15(2):117-20. PubMed ID: 18274834
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Microarray-based gene expression profiling as a clinical tool for breast cancer management: are we there yet?
    Correa Geyer F; Reis-Filho JS
    Int J Surg Pathol; 2009 Aug; 17(4):285-302. PubMed ID: 19103611
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gene expression profiling in breast cancer.
    Nasser SM
    J Med Liban; 2009; 57(2):83-8. PubMed ID: 19623883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endocrine therapy for early breast cancer.
    Hussain SA; Williams S; Stevens A; Rea DW
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):877-88. PubMed ID: 15485321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent advances in molecular genetics of breast cancer.
    Pavelić K; Gall-Troselj K
    J Mol Med (Berl); 2001 Oct; 79(10):566-73. PubMed ID: 11692153
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The value of gene expression profiles using micoarrays for the individualisation of adjuvant therapy after surgery for breast cancer].
    Klijn JG; de Vries EG
    Ned Tijdschr Geneeskd; 2005 Mar; 149(12):618-22. PubMed ID: 15813427
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen.
    Bertheau P; Turpin E; Rickman DS; Espié M; de Reyniès A; Feugeas JP; Plassa LF; Soliman H; Varna M; de Roquancourt A; Lehmann-Che J; Beuzard Y; Marty M; Misset JL; Janin A; de Thé H
    PLoS Med; 2007 Mar; 4(3):e90. PubMed ID: 17388661
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ROCK: a breast cancer functional genomics resource.
    Sims D; Bursteinas B; Gao Q; Jain E; MacKay A; Mitsopoulos C; Zvelebil M
    Breast Cancer Res Treat; 2010 Nov; 124(2):567-72. PubMed ID: 20563840
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An Overview Regarding Pharmacogenomics and Biomarkers Discovery: Focus on Breast Cancer.
    Scandolara TB; Barreto Pires BR; Vacario B; de Amorim ISS; Siqueira PB; Serpeloni JM; Mencalha AL; Bonvicino CR; Panis C
    Curr Top Med Chem; 2022; 22(20):1654-1673. PubMed ID: 35927918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.